Angela Bazzi
Profiles

Angela R Bazzi, PhD

Adjunct Associate Professor, Community Health Sciences - Boston University School of Public Health

Biography

Education

  • University of California, San Diego, PhD Field of Study: Public Health
  • Johns Hopkins University, MPH Field of Study: Public Health
  • University of Southern California, BA Field of Study: International Relations

Publications

  • Published on 2/4/2026

    Han BH, Chen S, Kepner WE, Bergstrom J, Freedman K, Coveney M, Bazzi AR. Pre-exposure Prophylaxis (PrEP) Eligibility and Awareness Among Older Adults with Opioid use Disorder. J Gen Intern Med. 2026 Feb 04. PMID: 41639371.

    Read At: PubMed
  • Published on 12/24/2025

    Wasserman E, Brewer B, Mandeville B, Welch C, Noh M, Bazzi AR, Biello K, Agénor M. "It Was Like a Baptism by Fire:" Sexual and Reproductive Healthcare Providers' Training Experiences Related to the Provision of Care to Black and Latina Women Who Use Substances in the United States. Community Health Equity Res Policy. 2025 Dec 24; 2752535X251409440. PMID: 41442083.

    Read At: PubMed
  • Published on 12/9/2025

    Eger WH, Huffaker SL, Forman E, Smith J, Akiba CF, Laurano R, Patel SV, Lambdin BH, Roth AM, Bazzi AR. Integration of safer smoking equipment in U.S. syringe services programs: Qualitative insights from program staff. Int J Drug Policy. 2026 Jan; 147:105106. PMID: 41371077.

    Read At: PubMed
  • Published on 10/24/2025

    Bazzi AR, Tookes HE, Bartholomew TS. Advancing pre-exposure prophylaxis (PrEP) implementation for people who use drugs: an introduction to and lessons from the special series. Addict Sci Clin Pract. 2025 Oct 24; 20(1):86. PMID: 41137118.

    Read At: PubMed
  • Published on 9/11/2025

    Roth AM, Forman E, Akiba CF, Eger WH, Laurano R, Huffaker SL, Patel SV, Smith J, Lambdin BH, Bazzi AR. HIV Services Implementation Within US Syringe Services Programs: A Qualitative Exploration. AIDS Patient Care STDS. 2025 Nov; 39(11):441-449. PMID: 40932685.

    Read At: PubMed
  • Published on 9/4/2025

    Weinstein ZM, Magane KM, Lodi S, Doeleman D, Ventura AS, Bazzi AR, Davoust M, Shea MG, Chen CA, Cheng A, Theisen J, Blakemore S, Saitz R. Associations between COVID impact domains and time to buprenorphine treatment disengagement. Am J Drug Alcohol Abuse. 2025; 51(6):776-785. PMID: 40906491.

    Read At: PubMed
  • Published on 8/28/2025

    Theisen J, Weinstein ZM, Davoust M, Ventura AS, Magane KM, Cheng A, Blakemore S, Blodgett J, Fielman S, Saitz R, Bazzi AR. Patient and Provider Perspectives on the Elimination of Urine Drug Testing in Office-Based Addiction Treatment. Subst Use Addctn J. 2026 Jan; 47(1):144-152. PMID: 40876939.

    Read At: PubMed
  • Published on 8/9/2025

    Paradise RK, Kimmel SD, Nurani A, Desmarais J, O'Malley S, Walley AY, Hoyos-Cespedes A, Clarke J, Taylor S, Dooley D, Bazzi AR. Building connection: overdose survivors' and professional service providers' perspectives on immediate post-overdose care. Int J Drug Policy. 2025 Nov; 145:104948. PMID: 40784254.

    Read At: PubMed
  • Published on 7/4/2025

    Plesons M, Eger WH, Crable EL, Hauschild MH, McElrath CC, Owens C, Forrest DW, Bazzi AR, De Los Santos N, Tookes HE, Bartholomew TS. Psychosocial consequences of xylazine and implications for harm reduction services. Drug Alcohol Depend Rep. 2025 Sep; 16:100357. PMID: 40687389.

    Read At: PubMed
  • Published on 5/27/2025

    Agénor M, Tipnis A, Byers M, Davis T, Noh M, Dunham R, Reyna K, Adesuyi Q, Bazzi AR, Biello KB. Structural barriers to sexual and reproductive health care among Black and Latina cisgender and transgender U.S. women who use drugs: a qualitative study. BMC Health Serv Res. 2025 May 27; 25(1):754. PMID: 40426121.

    Read At: PubMed

News & In the Media